Table 2. Summary of histopathologic characteristics.
| Characteristic | DCIS, n (%) | DCISM, n (%) | χ2 | P |
|---|---|---|---|---|
| Comedo‑type necrosis | 0.465 | 0.50 | ||
| Yes | 18 (27.3) | 8 (34.8) | ||
| No | 48 (72.7) | 15 (65.2) | ||
| Pathological grade | 13.355 | <0.001 | ||
| Grade 1–2 | 46 (69.7) | 6 (26.1) | ||
| Grade 3 | 20 (30.3) | 17 (73.9) | ||
| Estrogen receptor | 4.152 | 0.042 | ||
| Positive | 54 (81.8) | 14 (60.9) | ||
| Negative | 12 (18.2) | 9 (39.1) | ||
| Progesterone receptor | 4.940 | 0.03 | ||
| Positive | 55 (83.3) | 14 (60.9) | ||
| Negative | 11 (16.7) | 9 (39.1) | ||
| HER2 status | 9.283 | 0.009 | ||
| 0, 1+ | 12 (18.2) | 7 (30.4) | ||
| 2+ | 35 (53.0) | 4 (17.4) | ||
| 3+ | 19 (28.8) | 12 (52.2) | ||
| Ki‑67 index (%) | 3.844 | 0.050 | ||
| <20 | 44 (66.7) | 10 (43.5) | ||
| ≥20 | 22 (33.3) | 13 (56.5) | ||
DCIS, ductal carcinoma in situ; DCISM, ductal carcinoma in situ with microinvasion; HER2, human epidermal growth factor receptor 2.